Silence Therapeutics plc SLN

Set alert

Price alert · SLN

All alert types
19.80 USD +0.04 +0.18%

As of Nov 3, 12:13 PM ET

Bid
19.79 × 28
Ask
19.80 × 26
19.78 Day range 19.80
4.19 52-week range 19.87
YTD
+225.58%
1 year
+199.47%
Open
19.78
Prev close
19.76
Mkt cap
1.23B
Vol
133.00K
Avg vol
2.78M
EPS
-1.29
P/E
0.00
Div yield
0.00%
More statistics
Low
19.78
High
19.80
Forward P/E
-52.00
Beta
1.34
Short ratio
2.70
Inst. own
47.74%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
13.48
200-d avg
9.06
1y target
19.75

3M chart

Chart tools
Interval

Events in this range
  • Aug 10, 2026Earnings: -0.26; estimate -0.13866; surprise -87.51%
  • Aug 11, 2026Rating: Morgan Stanley · Overweight → Overweight
  • Oct 21, 2026Downgrade: HC Wainwright & Co. · Buy → Neutral
Signals (12)
NameDateAgo
SMA: BullishOct 19, 20262 weeks ago
SMA: BullishOct 19, 20262 weeks ago
MACD: Buy SignalOct 19, 20262 weeks ago
RSI: OverboughtOct 19, 20262 weeks ago
RSI: OversoldOct 16, 20262 weeks ago
RSI: OversoldOct 2, 20261 month ago
RSI: OversoldSep 29, 20261 month ago
SMA: BearishSep 18, 20261 month ago
SMA: BearishSep 11, 20261 month ago
MACD: Sell SignalAug 20, 20262 months ago
MACD: Buy SignalAug 10, 20262 months ago
RSI: OverboughtAug 10, 20262 months ago

Analyst view

Consensus: hold

Hold
Price target (mean) 19.75 -0.2% downside
Target (low)
19.00
Target (mean)
19.75
Target (high)
20.00
Ratings (0m) 5 1 buy · 4 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold4
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 5
  • 1 month ago 7
  • 2 months ago 7

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

SLN analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.09-0.09 – -0.09-0.15+40.0%20.83K-82.8%1
Next quarter-0.10-0.10 – -0.10-0.27+63.0%4.50K-82.3%1
Current year-0.365-0.37 – -0.36-1.85+80.3%328.76K-21.4%2
Next year-0.38-0.38 – -0.38-0.365-4.1%760.45K+131.3%2

Upgrades and downgrades

The latest rating changes

SLN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 21, 2026HC Wainwright & Co.DowngradeBuyNeutral
Aug 11, 2026Morgan StanleyMaintainedOverweightOverweight
Jun 24, 2026Cantor FitzgeraldInitiated—Overweight
Jun 17, 2026HC Wainwright & Co.ReiteratedBuyBuy
Mar 13, 2026HC Wainwright & Co.ReiteratedBuyBuy
Sep 16, 2025HC Wainwright & Co.ReiteratedBuyBuy
Aug 8, 2025Chardan CapitalMaintainedBuyBuy
Jun 13, 2025HC Wainwright & Co.ReiteratedBuyBuy
Jun 13, 2025Chardan CapitalMaintainedBuyBuy
May 9, 2025Goldman SachsMaintainedSellSell
May 9, 2025Morgan StanleyMaintainedOverweightOverweight
May 9, 2025Chardan CapitalMaintainedBuyBuy
Mar 7, 2025HC Wainwright & Co.ReiteratedBuyBuy
Mar 5, 2025Morgan StanleyMaintainedOverweightOverweight
Mar 4, 2025BMO CapitalMaintainedOutperformOutperform
Mar 4, 2025Goldman SachsMaintainedSellSell
Feb 11, 2025Goldman SachsInitiated—Sell
Feb 3, 2025HC Wainwright & Co.ReiteratedBuyBuy
Jan 29, 2025HC Wainwright & Co.ReiteratedBuyBuy
Dec 10, 2024Chardan CapitalMaintainedBuyBuy
Dec 9, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 20, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 14, 2024Chardan CapitalMaintainedBuyBuy
Oct 8, 2024Morgan StanleyReiteratedOverweightOverweight
Aug 30, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 16, 2024Chardan CapitalMaintainedBuyBuy
Jun 28, 2024Morgan StanleyMaintainedOverweightOverweight
Jun 28, 2024Chardan CapitalMaintainedBuyBuy
Jun 27, 2024HC Wainwright & Co.ReiteratedBuyBuy